[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
3. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both univariate analysis and Cox multivariate analysis, age, tumor site, tumor size, histological type, resection type, radical resection, lymphatic/venous invasion, depth of invasion, nodal status, metastasis, retrieved lymph nodes, metastatic lymph node ratio, and adjuvant chemotherapy were prognostic factors with these patients.
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Colak T, Akca T, Dirlik M, Caglikulekci M, Seyrek E, Cinel L, Bozdogan R, Aydin S: Signet ring cell carcinoma of the breast as a source of pelvic floor metastatic mass. A case report. Acta Chir Belg; 2005 Apr;105(2):224-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet ring cell carcinoma of the breast as a source of pelvic floor metastatic mass. A case report.
  • Primary signet ring cell carcinoma of the breast is a very rare tumour.
  • We present a case with pure signet ring cell carcinoma of the breast, which was recognized as metastasis on the pelvic floor, before developing breast symptoms and signs.
  • The histopathological examination revealed metastatic signet-ring cell carcinoma.
  • At the time of the first operation, the mammary glands were not suspicious.
  • An inflammatory sign developed in right breast two months after biopsy of the pelvic metastasis.
  • The histopathology of the breast incisional biopsy revealed primary pure signet ring cell carcinoma of the breast.
  • Because the oestrogen and progesterone receptor were negative in the tumoral tissue, the patient underwent chemotherapy followed by modified radical mastectomy, chemotherapy, and palliative resection of the metastatic mass.
  • To our knowledge, in English literature, we believe that this case is the first report of signet ring cell carcinoma of the breast presenting with pelvic floor metastasis without breast sign.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / therapy. Pelvic Neoplasms / secondary
  • [MeSH-minor] Adult. Biopsy, Needle. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Immunohistochemistry. Mastectomy, Modified Radical / methods. Neoplasm Staging. Pelvic Floor. Rare Diseases. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906923.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


5. Park KK, Park YW: Tonsillar metastasis of signet-ring cell adenocarcinoma of the colon. Ear Nose Throat J; 2010 Aug;89(8):376-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tonsillar metastasis of signet-ring cell adenocarcinoma of the colon.
  • Cases of primary colorectal signet-ring cell carcinoma metastatic to the tonsil are extremely rare.
  • She was treated with chemotherapy, but her disease continued to spread and she was eventually placed on comfort care and palliative radiation therapy.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Colonic Neoplasms / pathology. Head and Neck Neoplasms / secondary. Tonsillar Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20737376.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Kang MH, Kim SN, Kim NK, Park YI, Kim YW, Ryu KW, Lee JH, Lee JS, Park SR: Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy. Ann Surg Oncol; 2010 Dec;17(12):3163-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and prognostic factors of metastatic gastric carcinoma patients who experience gastrointestinal perforation during palliative chemotherapy.
  • BACKGROUND: We conducted the current study to investigate the clinical outcomes of metastatic gastric carcinoma (MGC) patients who experienced gastrointestinal (GI) perforation during palliative chemotherapy and to examine the prognostic factors associated with survival after perforation.
  • METHODS: We reviewed the medical records of patients at the Center for Gastric Cancer of the National Cancer Center, Korea who developed GI perforation during palliative chemotherapy between January 2001 and December 2008.
  • RESULTS: Of the 1,856 patients who received palliative chemotherapy for MGC, 32 patients (1.7%) developed GI perforation during chemotherapy.
  • Patients with perforation at the primary gastric site were more likely to have ulcerative gastric cancer lesion (90.5 vs. 40.0%, P = 0.034) or gastric tumor bleeding (28.6 vs. 0%, P = 0.298), and less likely to have Bormann type IV (14.3 vs. 60.0%, P = 0.062), than patients with perforation at nongastric sites.
  • In 14 patients (43.8%) who resumed chemotherapy after perforation, the disease control rate was 57.1%, and median overall survival (OS) after perforation was 7.5 months [95% confidence interval (CI), 6.0-9.0 months].
  • In all patients, median OS following perforation was 4.0 months (95% CI, 1.5-6.6 months), and multivariate analysis revealed that differentiated tumor histology, response to chemotherapy before perforation, and absence of septic shock at time of perforation were significantly associated with favorable OS after perforation.
  • CONCLUSIONS: As patients experiencing GI perforation during palliative chemotherapy have heterogeneous clinical presentation, we need to adopt different approaches in the management of the patients that are compatible with the favorable prognostic factors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Signet Ring Cell / drug therapy. Intestinal Perforation / chemically induced. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Palliative Care. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20585878.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Heidemann J, Gockel HR, Winde G, Herbst H, Domschke W, Lügering N: Signet-ring cell carcinoma of unknown primary location. Metastatic to lower back musculature - remission following FU/FA chemotherapy. Z Gastroenterol; 2002 Jan;40(1):33-6
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of unknown primary location. Metastatic to lower back musculature - remission following FU/FA chemotherapy.
  • The detection of gastrointestinal signet-ring cell carcinoma by endoscopy can be a diagnostic challenge.
  • We present a case of a metastasizing signet-ring cell carcinoma with unknown primary location arising in 71-year-old female.
  • Following 6 cycles of a routine intravenous FU/FA chemotherapy, an almost complete remission could be observed.
  • After 2 years of follow up, metastatic recurrence was detected to the lower back musculature.
  • This case report emphasizes the difficulties in diagnosing signet-ring cell carcinoma by endoscopy and demonstrates an unusual clinical course.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Fluorouracil / administration & dosage. Leucovorin / administration & dosage. Muscle Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / pathology. Abdominal Neoplasms / secondary. Aged. Back. Biopsy, Needle. Diagnosis, Differential. Endoscopy, Gastrointestinal. Female. Humans. Magnetic Resonance Imaging. Muscle, Skeletal / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11803498.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Chun JH, Kim HK, Lee JS, Choi JY, Lee HG, Yoon SM, Choi IJ, Ryu KW, Kim YW, Bae JM: Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol; 2004 Jan;34(1):8-13
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
  • BACKGROUND: The goal of this study is to determine the efficacy and toxicity of weekly irinotecan as second-line chemotherapy in advanced gastric cancer after failure of cisplatin-based regimen.
  • METHODS: Gastric cancer patients failing cisplatin-based chemotherapy received 125 mg/m(2) of irinotecan weekly for 4 weeks followed by 2-week rest, until disease progression.
  • At a median follow-up duration of 15.8 months, median time to progression and overall survival were 2.6 months (95% CI: 2.4-2.8) and 5.2 months (95% CI: 3.6-6.7), respectively.
  • These toxicities were manageable and there was no treatment-related death.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Salvage Therapy. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15020657.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


9. Katase K, Shimizu Y, Kobayashi Y, Hasumi K: [Chemotherapy with combination of UFT and cisplatin against metastatic ovarian tumor originating from gastric cancer]. Gan To Kagaku Ryoho; 2004 Jun;31(6):943-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy with combination of UFT and cisplatin against metastatic ovarian tumor originating from gastric cancer].
  • Krukenberg's tumor, an metastatic ovarian tumor originating from gastric cancer, is a disease with extremely poor prognosis, and it is rare for patients to survive for more than 2 years after the diagnosis.
  • We encountered a patient in whom a long-term good prognosis could be obtained probably because of the effects of chemotherapy after the ovarian tumor extraction.
  • Enhancement of the antitumor effects by the concomitant use of 5-FU and cisplatin has been attracting attention, and the methods of administration of these drugs have been investigated by numerous researchers as FP therapy.
  • It was characteristic to the treatment of our patient that 5-FU was administered in the form of oral UFT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Administration, Oral. Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Routes. Female. Humans. Hysterotomy. Ovariectomy. Prognosis. Tegafur / administration & dosage. Uracil / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15222118.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q20Q21Q62J / Cisplatin; FP protocol
  •  go-up   go-down


10. Romics I, Székely E, Szendroi A: Signet-ring cell carcinoma arising from the urinary bladder. Can J Urol; 2008 Oct;15(5):4266-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma arising from the urinary bladder.
  • INTRODUCTION: Signet-ring cell carcinoma of the urinary bladder can be primary - arising from the bladder wall or urachus remnants - or metastatic from tumors originating in the stomach, colon, or breast.
  • Saphir first described primary signet-ring cell cancer of the urinary bladder in 1955.
  • A transurethral biopsy showed signet-ring cell carcinoma.
  • Histological examination showed a primary signet-ring cell carcinoma of the bladder (pT3bN0M0).
  • Following surgery, the patient received adjuvant chemotherapy with cisplatin and fluorouracil.
  • CONCLUSIONS: Primary signet-ring cell carcinoma of the urinary bladder is an extremely rare tumor, accounting for approximately 0.24% of all bladder malignances.
  • Patients with this type of cancer generally have a poor prognosis.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Cystectomy. Cystoscopy. Female. Hematuria / etiology. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814817.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


11. Kodama T, Ishida H, Okino T, Okamoto R, Takahashi H, Hayashi N, Mori K, Noguchi M: [A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1159-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of complete response by TS-1 and paclitaxel combination chemotherapy for advanced gastric cancer].
  • We report a case in which combination chemotherapy of TS-1 and paclitaxel was effective for gastric cancer with malignant ascites, metastatic ovarian cancer and hydronephrosis.
  • Judging from the above issue, the stage was IV and the type was Borrmann 4.
  • The chemotherapy schedule was adjusted at the patient' s request without hindering her activities of daily living.
  • The patient was a 53-year-old woman who suffered from gastric cancer as having malignant ascites and metastatic ovarian tumor.
  • As an outpatient, she was treated with combination chemotherapy of TS-1 and paclitaxel for 2 cycles.
  • The adverse event was alopecia (grade 2), but she could continue the chemotherapy as an outpatient treatment.
  • After completing 5 cycles of chemotherapy, we recognized the primary tumor as an endoscopic complete response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Alopecia / chemically induced. Drug Administration Schedule. Drug Combinations. Female. Humans. Middle Aged. Ovarian Neoplasms / secondary. Oxonic Acid / administration & dosage. Oxonic Acid / adverse effects. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Quality of Life. Remission Induction. Tegafur / administration & dosage. Tegafur / adverse effects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912540.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


12. Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, Yakovleva ES, Garin AM, Tjulandin SA: A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol; 2010 Sep;21(9):1779-85
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
  • BACKGROUND: This retrospective study was carried out to evaluate the prognostic significance of clinical factors in patients treated for metastatic gastric cancer with second-line chemotherapy.
  • PATIENTS AND METHODS: We evaluated the prognostic significance of various clinical factors in 126 patients, who were treated with second-line chemotherapy.
  • RESULTS: Median progression-free and overall survival (OS) for second-line chemotherapy were 3.3 and 5.3 months, respectively, with an overall response rate of 11.1%.
  • Multivariate analysis identified three independent prognostic factors: performance status: Eastern Cooperative Oncology Group zero to one [hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.7-5.4], hemoglobin (Hb) level: >/=10 g/dl (HR 2.2, 95% CI 2.1-2.4) and time-to-progression (TTP) under first-line therapy: >/=5 months (HR 0.5, 95% CI 0.3-0.8).
  • CONCLUSIONS: With inadequate data from randomized controlled trials at the moment, our report indicates that second-line chemotherapy is effective and beneficial in patients with good performance status, higher Hb level along with higher TTP under first-line therapy.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150573.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Longo R, Morabito A, Carillio G, Lanzi G, Castellana MA, Amici S, Fanelli M, Gattuso D, Gasparini G: Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course. Int J Gastrointest Cancer; 2006;37(1):49-54
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course.
  • Mucinous colorectal cancer with signet ring cell aspects is a rare form of adenocarcinoma representing about 2-5% of large bowel neoplasms.
  • Local recurrence and distant metastases are common in spite of surgical operation and adjuvant treatment, conditioning a poor prognosis.
  • In our report we describe a case of a 41-yr-old patient with very aggressive untreated metastatic colorectal signet ring cell carcinoma.
  • The fulminant tumor progression was really unexpected and misled every possible medical interpretation, leading to rapid worsening of the patient's clinical conditions and no chance for chemotherapy treatment.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology. Neoplasm Metastasis / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1991 Sep-Oct;76(5):368-74 [1806439.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] Ann Surg Oncol. 1996 Jul;3(4):344-8 [8790846.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):77-99 [15000151.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):244-9 [15492759.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1022-5 [1654871.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1176-80 [10496558.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Tumori. 1996 Jul-Aug;82(4):408-12 [8890982.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1189-92 [7587762.001]
  • [Cites] Am J Med. 1976 Feb;60(2):273-8 [1062163.001]
  • (PMID = 17290081.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Karimata H, Nagahama M, Akamatsu M, Teruya J, Takaesu H, Nishimaki T: [A case of advanced gastric cancer with lung metastasis effectively treated by combination chemotherapy using S-1 and CDDP]. Gan To Kagaku Ryoho; 2007 Jun;34(6):925-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with lung metastasis effectively treated by combination chemotherapy using S-1 and CDDP].
  • We report a case with gastric cancer and lung metastasis,who responded remarkably to combination chemotherapy using S-1 and weekly CDDP.
  • Based on upper GI endoscopy and CT,type 3 gastric cancer associated with lung metastases was diagnosed.
  • The treatment resulted in the metastatic tumors in the lung disappearing after 1 course.
  • This combination chemotherapy proved useful for treating lung metastasis from gastric cancer in this patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Drug Combinations. Gastrectomy. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Remission Induction. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17565258.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


15. Busto Martín LA, Janeiro Pais M, González Dacal J, Chantada Abal V, Busto Castañón L: Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009. Arch Esp Urol; 2010 Mar;63(2):150-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009.
  • OBJECTIVES: To present a revision on the signet-ring cell bladder adenocarcinomas found in our department.
  • METHODS/RESULTS: We reviewed all the transurethral resections of the bladder (TURB) performed between 1990 and 2009 finding 9 cases of primary signet ring cell adenocarcinomas (4 pure and 5 mixed).
  • Definitive treatment was radical cystectomy with Bricker's urinary diversion in four patients, cysctectomy with Mainz's II diversion in one patient and palliative management with TURB in three cases and percutaneous nephrostomy in the remaining case.
  • We used adyuvant chemotherapy in three cases.
  • Only two patients were alive at the time of the study.
  • CONCLUSIONS: Signet-ring cell primary adenocarcinoma of the bladder is an uncommon type of tumor, with worse prognosis than transitional cell cancer.
  • It is important to discard other possible metastatic origins(like stomach, prostate, lung, or ovary) because the management will be different.
  • Radical cystectomy is the treatment of choice, with adyuvant chemotherapy if possible.
  • [MeSH-major] Carcinoma, Signet Ring Cell. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378938.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


16. Tsai HL, Huang YS, Hsieh JS, Huang TJ, Tsai KB: Signet-ring cell carcinoma of the rectum with diffuse and multiple skin metastases--a case report. Kaohsiung J Med Sci; 2002 Jul;18(7):359-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell carcinoma of the rectum with diffuse and multiple skin metastases--a case report.
  • Metastatic skin signet-ring cell carcinoma originating from stomach or colon is rare.
  • We reported a 45-year-old male who underwent abdominoperineal resection for an advanced rectal signet-ring cell carcinoma which developed multiple skin metastases in the scalp, face, neck, back and abdomen despite adjuvant chemotherapy performed postoperatively.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Rectal Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12380327.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


19. Blumenthal RD, Osorio L, Hayes MK, Horak ID, Hansen HJ, Goldenberg DM: Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother; 2005 Apr;54(4):315-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoembryonic antigen antibody inhibits lung metastasis and augments chemotherapy in a human colonic carcinoma xenograft.
  • PURPOSE: In addition to its use as a blood marker for many carcinomas, elevated expression of carcinoembryonic antigen (CEA, CD66e, CEACAM5) has been implicated in various biological aspects of neoplasia, especially tumor cell adhesion, metastasis, the blocking of cellular immune mechanisms, and having antiapoptosis functions.
  • However, it is not known if treatment with anti-CEA antibodies can affect tumor metastasis or alter the effects of cytotoxic drugs.
  • METHODS: In vitro, human colon cancer cell lines were treated with anti-CEA MAb IgG1, hMN-14 (labetuzumab), to assess direct effects on proliferation, as well as antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
  • In vivo studies were undertaken in nude mice bearing s.c. (local growth) or i.v. (metastatic model) GW-39 and LS174T human colon cancer grafts, to evaluate the MAb alone and in combination with either CPT-11 or 5-fluorouracil (5FU).
  • RESULTS: In vitro, labetuzumab did not induce apoptosis, nor did it affect tumor cell proliferation directly or by CDC, but it did inhibit tumor cell proliferation by ADCC.
  • In vivo, labetuzumab did not increase median survival in the GW-39 metastatic model unless the mice were pretreated with GM-CSF to increase their peripheral WBC counts; GM-CSF alone was ineffective.
  • When nude mice received labetuzumab with CPT-11 or 5FU, median survival increased significantly as compared to the drug or antibody alone.
  • CONCLUSIONS: Labetuzumab, a CEA-specific MAb, induces effector-cell function in vitro against CEA-positive colonic tumor cells, and also inhibits growth of lung metastasis when CEA expression is up-regulated or if peripheral WBCs are increased.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Camptothecin / analogs & derivatives. Carcinoembryonic Antigen / immunology. Carcinoma, Signet Ring Cell / prevention & control. Colonic Neoplasms / therapy. Lung Neoplasms / prevention & control
  • [MeSH-minor] Animals. Antibody-Dependent Cell Cytotoxicity. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Cell Proliferation / drug effects. Combined Modality Therapy. Complement System Proteins / immunology. Drug Resistance, Neoplasm. Female. Fluorouracil / administration & dosage. Humans. Mice. Mice, Nude. Survival Rate. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15592930.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Carcinoembryonic Antigen; 7673326042 / irinotecan; 9007-36-7 / Complement System Proteins; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Mohile SG, Schleicher L, Petrylak DP: Treatment of metastatic urachal carcinoma in an elderly woman. Nat Clin Pract Oncol; 2008 Jan;5(1):55-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic urachal carcinoma in an elderly woman.
  • BACKGROUND: A 67-year-old woman with a history of smoking presented with abdominal pain and hematuria.
  • No adjuvant therapy was administered.
  • DIAGNOSIS: Metastatic urachal adenocarcinoma.
  • MANAGEMENT: Surgical excision combined with cystectomy and pelvic lympadenectomy, chemotherapy with 5-fluorouracil, leucovorin, and irinotecan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / secondary. Cystectomy. Lymph Node Excision. Pelvic Neoplasms / secondary. Urachus. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097457.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


21. Zhu XD, Hu XC, Zhang W, Hong XN, Guo Y, Yin JL, Wang ZH, Li J: Chloroxoquinoline in combination with epirubicin, cisplatin and 5-fluorouracil in metastatic gastric cancer. Hepatogastroenterology; 2009 Mar-Apr;56(90):555-60
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chloroxoquinoline in combination with epirubicin, cisplatin and 5-fluorouracil in metastatic gastric cancer.
  • BACKGROUND/AIMS: The aim of this study was to evaluate the efficacy and tolerability of combination chemotherapy with epirubicin, cisplatin, 5-fluorouracil (ECF regimen), and Chloroxoquinoline in patients with metastatic gastric cancer.
  • METHODOLOGY: Twenty-two patients with histologically confirmed metastatic gastric adenocarcinoma were treated with a combination of epirubicin 50 mg/m2 (day 1), cisplatin 60 mg/m2 (day 1), 5-fluorouracil 500 mg/m2 (days 1 to 5), and Chloroxoquinoline 400 mg (days 1 to 21), with the cycle repeated every three weeks.
  • One case of (5%) complete response, seven of (35%) partial response, nine (45%) of stable disease, and three (15%) of progressive disease were observed, giving an overall treatment response rate of 40%.
  • Median survival time was 9.4 months, median progression-free survival was 6.1 months, and the 1-year survival rate was 25%.
  • Both hematologic and non-hemotologic toxicities were well tolerated and no treatment-related deaths occurred.
  • CONCLUSION: The combination regimen demonstrated comparable efficacy and acceptable safety profiles in patients with metastatic gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Molecular Structure. Proportional Hazards Models. Quinolines. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579642.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinolines; 0 / chloroxoquinoline; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU: In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs; 2005 Jan;16(1):87-91
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
  • Individual response of disseminated cancer to chemotherapy is unpredictable.
  • In vitro chemotherapy-induced apoptosis can be measured and might be a method to evaluate in vivo activity of tested drugs.
  • In this report, tumor cells of a patient with signet cell carcinoma of the stomach and diffuse bone marrow infiltration were cultured and tested for in vitro chemosensitivity.
  • The drugs gemcitabine, oxaliplatin and zoledronic acid were found to induce in vitro tumor cell apoptosis synergistically, and subsequently were used as combination chemotherapy regimen.
  • An initially existing disseminated intravascular coagulopathy quickly resolved and after 6 months of treatment on ongoing complete response was induced, thus confirming the results of in vitro chemosensitivity testing.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Deoxycytidine / analogs & derivatives. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diphosphonates / administration & dosage. Drug Screening Assays, Antitumor. Humans. Imidazoles / administration & dosage. Male. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Predictive Value of Tests. Remission Induction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613910.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6XC1PAD3KF / zoledronic acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


23. Yan D, Dai H: [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Mar;31(3):217-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
  • OBJECTIVE: The aim of this study is to investigate the efficiency and toxicity of the FOLFOX regimen, the combination of oxaliplatin (L-OHP), 5-fluorouracil (5-Fu) and calcium folinate (CF), for patients with locally advanced or metastatic gastric cancer.
  • METHODS: Ninety-six patients with locally advanced or metastatic gastric adenocarcinoma, including 72 males and 24 females, were treated with FOLFOX regimen: L-OHP 85 mg/m(2) iv in 2 hours on D1, CF 200 mg/m(2) iv in 2 hours on D1 and D2, 5-Fu 400 mg/m(2) iv on D1 and D2, and then continuous infusion of it at a dose of 600 mg/m(2) for 44 hours.
  • The median cycle of the chemotherapy was 6 (range: 1 to 12 cycles).
  • RESULTS: Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy.
  • Ten of those were still alive, while the other 11 died of the disease, with a median disease free survival time of 24.0 months and 3-year survival rate of 51.8%.
  • The other 75 received only palliative chemotherapy due to non-operable advanced disease.
  • CONCLUSION: In terms of efficacy and safety, the FOLFOX regimen is effective and well tolerable for patients with locally advanced or metastatic gastric cancers either as adjuvant or palliative chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / secondary. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Leucovorin / therapeutic use. Lymphatic Metastasis. Male. Middle Aged. Neutropenia / chemically induced. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Organoplatinum Compounds / therapeutic use. Palliative Care. Remission Induction. Survival Rate. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19615264.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


24. Zhao JZ, Wang G, Zhang RP, Liang H: [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Feb;13(2):129-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological features and prognosis of 68 patients with metastatic ovarian tumors from the gastric cancer].
  • OBJECTIVE: To investigate the clinicopathological features and prognosis of metastatic ovarian tumors from gastric cancer.
  • METHODS: Clinical data of 68 patients with metastatic ovarian carcinoma were reviewed retrospectively.
  • Pathological type was signet-ring cell carcinoma in 52.9% of the cases.
  • Most of them underwent surgical treatment or chemotherapy or both.
  • Univariable analysis revealed that resection of gastric cancer, lymphatic metastasis, pathologic type of metastatic ovarian tumor, extent of metastatic lesion, cytoreductive surgery and chemotherapy for metastatic ovarian carcinoma were associated with the prognosis.
  • Multivariable analysis revealed that cytoreductive surgery and extent of metastatic lesion were independent factors.
  • Patients with metastatic lesion confined to the ovaries had a median overall survival of 16.0 months as compared to 8.6 months for those with more extensive metastases (P<0.01), and had a median progression-free survival of 8.2 months as compared to 4.1 months for those with more extensive metastases (P<0.05).
  • Optimal cytoreduction was also associated with a significantly longer median progression-free survival (11.0 months) as compared to suboptimal cytoreduction median progression-free survival (3.1 months) (P<0.01).
  • CONCLUSIONS: Prognosis of patients with metastatic ovarian carcinoma from gastric cancer is quite poor.
  • Extent of metastatic lesion is an independent factor.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186624.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Kadikoylu G, Barutca S, Tataroglu C, Kafkas S, Erpek H, Meydan N, Yavasoglu I, Bolaman Z: Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman. Transfus Apher Sci; 2010 Feb;42(1):39-42
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
  • Thrombotic thrombocytopenic purpura (TTP) was diagnosed and therapeutic plasma exchange was performed on the patient.
  • Signet ring cell adenocarcinoma stained with cytokeratin 7 and mucicarmine was seen on ovaries and bone marrow, after the pathological examination.
  • Although chemotherapy including cis-platinum, infusional 5-fluorouracil, and calcium leucovorin were administered in two courses, she died from respiratory failure.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bone Marrow Neoplasms / secondary. Carcinoma, Signet Ring Cell / secondary. Neoplasms, Unknown Primary / complications. Ovarian Neoplasms / secondary. Purpura, Thrombotic Thrombocytopenic / etiology
  • [MeSH-minor] Abdomen, Acute / etiology. Abdomen, Acute / surgery. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Hemoperitoneum / complications. Hemoperitoneum / surgery. Humans. Laparotomy. Leucovorin / administration & dosage. Plasma Exchange. Respiratory Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19926523.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, Park BB, Lim HY, Han MJ, Park JO, Park YS: Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol; 2007 Jan;18(1):88-92
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
  • BACKGROUND: This nonrandomized open label phase II study evaluated the efficacy and safety of FOLFOXIRI in metastatic or recurrent gastric cancer patients.
  • PATIENTS AND METHODS: Patients with histologically proven, metastatic gastric adenocarcinoma, aged 18-70 years, performance status zero to two, no prior chemotherapy, and with signed written informed consent were eligible.
  • Treatment consisted of irinotecan 150 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, leucovorin 100 mg/m2 day 1, and 5-fluorouracil 2000 mg/m2 as a 48-h continuous infusion starting on day 1, which was repeated every 2 weeks.
  • In total, 386 cycles were administered with a median of nine cycles per patient (range 1-12 cycles) and 45 of 48 patients were assessable for treatment response.
  • The median survival of all patients was 14.8 months and the median time to progression was 9.6 months.
  • CONCLUSIONS: The modified FOLFOXIRI combination chemotherapy showed a very promising preliminary antitumor activity and was generally well tolerated as a first-line treatment of patients with metastatic gastric cancer.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971670.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


27. Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS: The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):97-101
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries.
  • STUDY DESIGN: From September 1994 to December 2006, 158 patients with pathologically confirmed metastatic tumors to the ovaries at Samsung Medical Center (SMC) were included in this study.
  • Krukenberg tumor (pathologically proven signet ring cell carcinoma) was found in 34 cases: stomach (25), colon (2), appendix (1), and unknown (6).
  • The overall 5-year survival was 7.2% and the median survival time was 15 months.
  • The median survival times according to the primary tumor site showed significant differences (p=0.002) and were as follows: stomach 12 months, colon 17 months.
  • The median survival in cases with residual disease <2 cm vs. >2 cm was 26 months vs. 15 months (p=0.017) and the median survival with vs. without adjuvant chemotherapy was 16 months vs. 10 months (p=0.001).
  • CONCLUSION: Cytoreductive surgery and post-operative adjuvant chemotherapy had a beneficial effect on survival in selected patients.
  • [MeSH-minor] Female. Humans. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018420.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


28. Kunz J, Makek M: [Primary adenocarcinoma of the appendix as differential diagnosis of advanced ovarian carcinoma]. Praxis (Bern 1994); 2006 Aug 16;95(33):1217-25
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of the appendix as differential diagnosis of advanced ovarian carcinoma].
  • [Transliterated title] Das primäre Adenokarzinom der Appendix als Differentialdiagnose des fortgeschrittenen Ovarialkarzinoms.
  • Metastatic mucinous adenocarcinomas of the appendix are only reported as case histories.
  • Advanced primary adenocarcinomas of the appendix with ovarian metastases cannot be distinguished intraoperatively from a FIGO III ovarian carcinoma.
  • The pathologist makes the definitive diagnosis.
  • Surgical therapy of the isolated primary appendiceal carcinoma consists of a hemicolectomy--an appendectomy in favourable cases--and, in the case of a metastasised carcinoma, according to the guidelines for an advanced ovarian or colon carcinoma.
  • The effect of chemotherapy is insufficiently documented.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939122.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Kobayashi O, Murakami H, Yoshida T, Cho H, Yoshikawa T, Tsuburaya A, Sairenji M, Motohashi H, Sugiyama Y, Kameda Y: Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center. World J Surg; 2004 Jun;28(6):548-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center.
  • The clinical features of metastatic gastric tumors (MGTs) have not been well documented.
  • The primary tumors included one each of squamous cell carcinoma of the esophagus, signet-ring cell carcinoma of the breast, large-cell or small-cell carcinoma of the lung, renal cell carcinoma, hepatocellular carcinoma, squamous cell or epidermoid carcinoma of the uterus, and melanoma.
  • Although six patients underwent gastrectomy, macroscopic eradication of gastric metastatic disease was accomplished in only four, in whom a UICC R0 resection was possible in only two.
  • Five patients were treated by chemotherapy with no apparent survival benefit.
  • A median survival after MGT diagnosis was 170 days (range 16-892 days) for all cases, 384 days for those who underwent gastrectomy (n = 6), and 27 days for those without active treatment (n = 3) (p = 0.002).

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):152-5 [7959258.001]
  • [Cites] Int J Clin Pract. 2002 Oct;56(8):623-5 [12425377.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1581-4 [11149006.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):25-30 [11957041.001]
  • [Cites] JAMA. 1974 Aug 12;229(7):825-6 [4407823.001]
  • [Cites] Am J Surg. 1991 Sep;162(3):208-11 [1718180.001]
  • [Cites] Indian J Gastroenterol. 1992 Apr;11(2):88 [1428039.001]
  • [Cites] Radiology. 1972 Oct;105(1):1-11 [5066554.001]
  • [Cites] Dig Dis Sci. 1990 Nov;35(11):1421-5 [2226104.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Mar;123(3):512-21 [1124830.001]
  • [Cites] J Gastroenterol. 1994 Feb;29(1):71-5 [7515309.001]
  • [Cites] Gastrointest Endosc. 2000 Aug;52(2):273-5 [10922110.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2235-41 [4052968.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Can J Surg. 1962 Oct;5:438-41 [13954414.001]
  • [Cites] Acta Oncol. 1993;32(4):459-60 [8396398.001]
  • [Cites] Acta Chir Belg. 2000 Sep-Oct;100(5):228-30 [11143327.001]
  • [Cites] Thorac Cardiovasc Surg. 1993 Oct;41(5):318-20 [8303703.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Clin Gastroenterol. 1998 Mar;26(2):153-4 [9563931.001]
  • [Cites] Am J Surg. 1960 Jan;99:94-6 [13814449.001]
  • [Cites] Endoscopy. 1996 Feb;28(2):262 [8739747.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):170-2 [6274500.001]
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):566-7 [12297779.001]
  • [Cites] J Gastroenterol. 1994 Aug;29(4):495-500 [7951861.001]
  • [Cites] Am J Gastroenterol. 1985 Jan;80(1):67-9 [3966457.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):363-5 [11474262.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1209-12 [12168927.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • (PMID = 15366743.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Takeyoshi I, Iwanami K, Yamada T, Kawate S, Hamada K, Sunose Y, Yoshida M, Horiguchi J, Ohwada S, Sasaki A, Morishita Y: Advanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report. Hepatogastroenterology; 2005 Jan-Feb;52(61):322-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological examination of biopsy specimens from the edematous lesion revealed signet-ring-cell carcinoma.
  • Computed tomography demonstrated a thickening of the gastric wall, severe ascites, and peritoneal dissemination in the Douglas pouch.
  • By completion of the first course of treatment, the ascites had disappeared, the tumor in the Douglas pouch had shrunk, and the thickening of the gastric wall had lessened.
  • In addition, the fold in the stomach appeared by endoscopic examination to have resumed its normal thickness, no malignant cells were detected in a biopsy, and the thymidine phosphorylase activity in the tumor tissue was two-fold greater than that before chemotherapy.
  • After three treatment courses, the number of apoptotic cells had apparently increased compared with the prechemotherapy number.
  • The only adverse drug reactions that were observed were grade 2 alopecia and grade 1 myalgia.
  • After thirteen courses of chemotherapy over the past one year, both primary and metastatic lesions seem to be regressing.
  • This case study suggests that paclitaxel plus doxifluridine therapy is effective and well-tolerated in non-resectable gastric cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783060.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 039LU44I5M / Floxuridine; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.- / Pyrimidine Phosphorylases; P88XT4IS4D / Paclitaxel; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


31. Sakai Y, Saotome T, Fujimori M, Shimizu S, Inkyo T, Yugeta H, Ohbu M, Koma Y, Sato T, Nagashima F, Hayasaka A, Fukuyama Y, Tsuchiya S, Tsuyuguchi T, Saisho H: [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1319-22
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A pilot study of TS-1+CDDP therapy for highly advanced stage IV gastric cancer].
  • We performed a pilot study of combination chemotherapy with TS-1 and cisplatin for highly advanced gastric cancer.
  • An objective response was obtained in 9 cases (75.0%) of primary sites and 6 cases of metastatic sites.
  • The median survival time is 244 days.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Drug Combinations. Female. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Pilot Projects. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184932.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Lordick F, Grenacher L, Röcken C, Ebert M, Moehler M, Schumacher G: [Diagnosis and treatment of gastric cancer]. Dtsch Med Wochenschr; 2010 Aug;135(34-35):1671-82; quiz 1683-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of gastric cancer].
  • [Transliterated title] Diagnostik und Therapie des Magenkarzinoms.
  • A sophisticated staging should include high-resolution computed tomography of the thorax, abdomen and pelvis and video-documented endoscopy and endoscopic ultrasound.
  • In the stages II and III perioperative chemotherapy has been established as a standard of care and should be applied.
  • In the metastatic setting, treatment goals are palliative.
  • Chemotherapy can prolong survival, improve symptoms and can help to maintain a better quality of life.
  • Combination chemotherapy including a platinum compound and a fluoropyrimidine regarded as standard.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cisplatin / administration & dosage. Endoscopy, Digestive System. Epirubicin / administration & dosage. Esophagectomy. Fluorouracil / administration & dosage. Gastrectomy. Gastric Mucosa / pathology. Humans. Laparoscopy. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart-New York.
  • (PMID = 20721843.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FPEPIR regimen
  • [Number-of-references] 40
  •  go-up   go-down


33. Suzuki T, Iwabuchi M, Matsuda Y, Imai G, Yokoyama H, Mochida A, Takahashi H, Shiina M, Yamada K, Ishibashi J, Suzuki S, Chida N, Tadokoro K: [Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1]. Gan To Kagaku Ryoho; 2003 Jan;30(1):133-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1].
  • In the present report, we describe the treatment results of paclitaxel in patients with metastatic gastric cancer previously treated with TS-1 or combination chemotherapy of TS-1 and CDDP.
  • Case 1: A 52-year-old male patient with gastric cancer and multiple liver metastases was treated by weekly infusion of paclitaxel as a 2nd line chemotherapy.
  • The adverse effects observed with this drug were leucocytopenia and liver dysfunction, both of which improved soon.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Signet Ring Cell / drug therapy. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Remission Induction. Tegafur / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12557719.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Saka M, Katai H, Fukagawa T, Nijjar R, Sano T: Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer; 2008;11(4):214-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Nineteen (8%) of the 238 patients with lymph node-positive disease developed recurrence.
  • The interval between surgery and the detection of recurrence ranged from 3 to 98 months, with a median of 26 months.
  • Multivariate analysis demonstrated that the number of metastatic nodes was an independent risk factor for recurrence.
  • Patients with seven or more metastatic nodes had the highest rate of recurrence, at 38%.
  • These high-risk patients may obtain additional survival benefit if targeted with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Signet Ring Cell / secondary. Lymphatic Metastasis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2767-73 [15199090.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2282-7 [12805327.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1468-76 [17948223.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):401-5 [11986193.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3174-8 [8242540.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1035-42 [12153632.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):209-14 [12865463.001]
  • [Cites] Surgery. 1989 May;105(5):585-92 [2705096.001]
  • [Cites] Ann Surg Oncol. 2001 Aug;8(7):605-10 [11508623.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):235-9 [15609385.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2005 Jan;200(1):15-9 [15631915.001]
  • [Cites] Langenbecks Arch Surg. 2004 Apr;389(2):69-74 [14985987.001]
  • [Cites] Gastric Cancer. 2001;4(2):54-9 [11706761.001]
  • [Cites] Lancet. 1999 Jul 24;354(9175):273-7 [10440302.001]
  • [Cites] Dig Surg. 2003;20(2):148-53 [12686784.001]
  • (PMID = 19132483.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Kobayashi M, Araki K, Matsuura K, Kawai S, Moriki T: Early gastric cancer giving rise to bone and brain metastases--a review of the Japanese literature. Hepatogastroenterology; 2002 Nov-Dec;49(48):1751-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological findings revealed the signet-ring-cell cancer confined to the mucosa and no lymph node metastasis.
  • Bone scintigraphy demonstrated multiple accumulation and bone biopsy of the sacrum revealed the metastatic gastric cancer.
  • She underwent chemotherapy and radiation, however, later complained of nausea, vomiting, and diminished visual acuity.
  • Brain computed tomography revealed multiple brain metastasis.
  • We reviewed the 39 reported cases of early gastric cancer with bone metastasis in Japan, which suggests that signet-ring-cell carcinoma and poorly differentiated carcinoma have a possibility of bone metastasis even though the early gastric cancer is confined to the mucosa.
  • [MeSH-major] Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397785.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Number-of-references] 11
  •  go-up   go-down


36. Omatsu T, Ichikawa H, Kawahito Y, Ashihara E, Yamamoto A, Kadoya M, Takegami T, Takanashi Y, Naito Y, Yoshida N, Sugino S, Yoshikawa T: [A case of advanced gastric cancer with bone metastases and DIC responding to oral administration of TS-1]. Gan To Kagaku Ryoho; 2003 Jun;30(6):869-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, both the primary gastric tumor and metastatic bone lesions were reduced in size by the treatment with TS-1.
  • TS-1 appears to be an effective therapeutic agent for advanced gastric cancer with DIC or bone metastases.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Bone Neoplasms / secondary. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / secondary. Disseminated Intravascular Coagulation / drug therapy. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Drug Administration Schedule. Drug Combinations. Humans. Male

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12852359.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


37. Rossi G, Murer B, Cavazza A, Losi L, Natali P, Marchioni A, Migaldi M, Capitanio G, Brambilla E: Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression. Am J Surg Pathol; 2004 Apr;28(4):442-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eleven cases were predominantly composed of tall, columnar goblet cells (goblet cell-type MC), while 2 consisted of signet-ring tumor cells (signet-ring cell-type MC).
  • Postoperative chemotherapy was performed in 3 cases.
  • All patients with goblet cell-type MC were alive and well, while the 2 patients with signet-ring cell-type MC died of disease.
  • Immunohistochemically, all the 11 goblet cell-type MCs were strongly stained with CDX-2 and MUC2, 8 reacted with TTF-1, 6 with cytokeratin 20 (CK20), 9 with cytokeratin 7 (CK7), and 2 with MUC-5AC.
  • Conversely, the two signet-ring cell-type MCs were stained with TTF-1, CK7, and MUC5AC but were negative for CDX-2, MUC2, and CK20.
  • Surfactant apoprotein-A (SP-A) was positive in four goblet cell-type and one signet-ring cell-type MC.
  • 1) the goblet cell-type, presenting a more indolent clinical behavior and frequently co-expressing markers of intestinal and pulmonary differentiation; and 2) the more aggressive signet-ring cell-type, which retains only markers of pulmonary origin.
  • On morphologic and immunohistochemical grounds, MCs are easily distinguishable from m-BAC.
  • Since goblet cell-type MC strongly stains with CDX2, MUC2, and CK20, differential diagnosis with metastatic colorectal carcinoma is very challenging and requires appropriate clinical correlation.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2004 Sep;28(9):1254-5 [15316331.001]
  • (PMID = 15087663.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


38. Kobayashi S, Noda M, Isogami K, Hasumi T: c-myc amplification and enhancement of sensitivity to cytosine arabinoside: an in vitro and in vivo study on four sublines established from a pulmonary adenocarcinoma. Surg Today; 2002;32(7):608-17
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Meticulous treatment strategies taking tumor heterogeneity into account are considered essential to achieve breakthroughs in current cancer therapy.
  • The 88-2T and 88-2 tumors revealed a well-differentiated adenocarcinoma; the 88-2F tumor revealed a large cell-like carcinoma resembling the metastatic tumor in the lymph nodes; and the 88-2FA tumor was composed of signet-ring cells.
  • Sensitivity to cytosine arabinoside (Ara C) was specifically increased in the 88-2F cell line, alone.
  • CONCLUSIONS: These sublines demonstrate that human pulmonary adenocarcinoma has various types of heterogeneity within the primary tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Non-Small-Cell Lung / pathology. Cytarabine / pharmacology. Gene Amplification. Genes, myc / genetics. Lung Neoplasms / pathology
  • [MeSH-minor] Cell Division. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Neoplasm Metastasis. Phenotype. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111518.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down






Advertisement